453 related articles for article (PubMed ID: 26839018)
1. Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma.
Ghasimi S; Wibom C; Dahlin AM; Brännström T; Golovleva I; Andersson U; Melin B
J Neurooncol; 2016 May; 127(3):483-92. PubMed ID: 26839018
[TBL] [Abstract][Full Text] [Related]
2. Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies.
Di Stefano AL; Enciso-Mora V; Marie Y; Desestret V; Labussière M; Boisselier B; Mokhtari K; Idbaih A; Hoang-Xuan K; Delattre JY; Houlston RS; Sanson M
Neuro Oncol; 2013 May; 15(5):542-7. PubMed ID: 23161787
[TBL] [Abstract][Full Text] [Related]
3. Replication of GWAS identifies RTEL1, CDKN2A/B, and PHLDB1 SNPs as risk factors in Portuguese gliomas patients.
Viana-Pereira M; Moreno DA; Linhares P; Amorim J; Nabiço R; Costa S; Vaz R; Reis RM
Mol Biol Rep; 2020 Feb; 47(2):877-886. PubMed ID: 31721021
[TBL] [Abstract][Full Text] [Related]
4. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
[TBL] [Abstract][Full Text] [Related]
5. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.
Chai RC; Zhang KN; Chang YZ; Wu F; Liu YQ; Zhao Z; Wang KY; Chang YH; Jiang T; Wang YZ
Carcinogenesis; 2019 Oct; 40(10):1229-1239. PubMed ID: 31157866
[TBL] [Abstract][Full Text] [Related]
6. Known glioma risk loci are associated with glioma with a family history of brain tumours -- a case-control gene association study.
Melin B; Dahlin AM; Andersson U; Wang Z; Henriksson R; Hallmans G; Bondy ML; Johansen C; Feychting M; Ahlbom A; Kitahara CM; Wang SS; Ruder AM; Carreón T; Butler MA; Inskip PD; Purdue M; Hsing AW; Mechanic L; Gillanders E; Yeager M; Linet M; Chanock SJ; Hartge P; Rajaraman P
Int J Cancer; 2013 May; 132(10):2464-8. PubMed ID: 23115063
[TBL] [Abstract][Full Text] [Related]
7. Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis.
Walsh KM; Rice T; Decker PA; Kosel ML; Kollmeyer T; Hansen HM; Zheng S; McCoy LS; Bracci PM; Anderson E; Hsuang G; Wiemels JL; Pico AR; Smirnov I; Molinaro AM; Tihan T; Berger MS; Chang SM; Prados MD; Lachance DH; Sicotte H; Eckel-Passow JE; Wiencke JK; Jenkins RB; Wrensch MR
Neuro Oncol; 2013 Aug; 15(8):1041-7. PubMed ID: 23733245
[TBL] [Abstract][Full Text] [Related]
8. Interaction between 5 genetic variants and allergy in glioma risk.
Schoemaker MJ; Robertson L; Wigertz A; Jones ME; Hosking FJ; Feychting M; Lönn S; McKinney PA; Hepworth SJ; Muir KR; Auvinen A; Salminen T; Kiuru A; Johansen C; Houlston RS; Swerdlow AJ
Am J Epidemiol; 2010 Jun; 171(11):1165-73. PubMed ID: 20462933
[TBL] [Abstract][Full Text] [Related]
9. Prognostic stratification of patients with anaplastic gliomas according to genetic profile.
Dehais C; Laigle-Donadey F; Marie Y; Kujas M; Lejeune J; Benouaich-Amiel A; Pedretti M; Polivka M; Xuan KH; Thillet J; Delattre JY; Sanson M
Cancer; 2006 Oct; 107(8):1891-7. PubMed ID: 16986124
[TBL] [Abstract][Full Text] [Related]
10. Effect of CDKN2A/B rs4977756 polymorphism on glioma risk: a meta-analysis of 16 studies including 24077 participants.
Qi X; Wan Y; Zhan Q; Yang S; Wang Y; Cai X
Mamm Genome; 2016 Feb; 27(1-2):1-7. PubMed ID: 26577493
[TBL] [Abstract][Full Text] [Related]
11. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
12. Joint associations between genetic variants and reproductive factors in glioma risk among women.
Wang SS; Hartge P; Yeager M; Carreón T; Ruder AM; Linet M; Inskip PD; Black A; Hsing AW; Alavanja M; Beane-Freeman L; Safaiean M; Chanock SJ; Rajaraman P
Am J Epidemiol; 2011 Oct; 174(8):901-8. PubMed ID: 21920947
[TBL] [Abstract][Full Text] [Related]
13. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
[TBL] [Abstract][Full Text] [Related]
14. Combination genetic signature stratifies lower-grade gliomas better than histological grade.
Chan AK; Yao Y; Zhang Z; Shi Z; Chen L; Chung NY; Liu JS; Li KK; Chan DT; Poon WS; Wang Y; Zhou L; Ng HK
Oncotarget; 2015 Aug; 6(25):20885-901. PubMed ID: 26369702
[TBL] [Abstract][Full Text] [Related]
15. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
16. Shallow whole-genome sequencing: a useful, easy to apply molecular technique for CNA detection on FFPE tumor tissue-a glioma-driven study.
Van der Eecken K; Van der Linden M; Raman L; Creytens D; Dedeurwaerdere F; De Winne K; Ferdinande L; Lammens M; Menten B; Rottiers I; Van Gaever B; Van den Broecke C; Van de Vijver K; Van Roy N; Verbeke S; Van Dorpe J
Virchows Arch; 2022 Mar; 480(3):677-686. PubMed ID: 35034191
[TBL] [Abstract][Full Text] [Related]
17. Detection and Correlation of Single and Concomitant
Pessôa IA; Amorim CK; Ferreira WAS; Sagica F; Brito JR; Othman M; Meyer B; Liehr T; de Oliveira EHC
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151164
[TBL] [Abstract][Full Text] [Related]
18. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility.
Wrensch M; Jenkins RB; Chang JS; Yeh RF; Xiao Y; Decker PA; Ballman KV; Berger M; Buckner JC; Chang S; Giannini C; Halder C; Kollmeyer TM; Kosel ML; LaChance DH; McCoy L; O'Neill BP; Patoka J; Pico AR; Prados M; Quesenberry C; Rice T; Rynearson AL; Smirnov I; Tihan T; Wiemels J; Yang P; Wiencke JK
Nat Genet; 2009 Aug; 41(8):905-8. PubMed ID: 19578366
[TBL] [Abstract][Full Text] [Related]
19. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C
J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377
[TBL] [Abstract][Full Text] [Related]
20. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.
Labussière M; Di Stefano AL; Gleize V; Boisselier B; Giry M; Mangesius S; Bruno A; Paterra R; Marie Y; Rahimian A; Finocchiaro G; Houlston RS; Hoang-Xuan K; Idbaih A; Delattre JY; Mokhtari K; Sanson M
Br J Cancer; 2014 Nov; 111(10):2024-32. PubMed ID: 25314060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
